Drug Patent List
Oppositions
Newsletter
Weekly Digest

Pharsight

Cannabidiol Patent Expiration

Cannabidiol is Used for reducing convulsive seizure frequency in patients with Dravet syndrome, Lennox-Gastaut syndrome, and tuberous sclerosis complex. It was first introduced by Jazz Pharmaceuticals Research Uk Ltd in its drug Epidiolex on Sep 28, 2018.


Cannabidiol Patents

Given below is the list of patents protecting Cannabidiol, along with the drug name that holds that patent and the company name owning that drug.

Drug Used in Drug Patent Number Drug Patent Title Drug Patent Expiry Drug Owner
Epidiolex US10092525 Use of cannabinoids in the treatment of epilepsy Jun 17, 2035 Jazz Pharms Res
Epidiolex US10111840 Use of cannabinoids in the treatment of epilepsy Jun 17, 2035 Jazz Pharms Res
Epidiolex US10137095 Use of cannabinoids in the treatment of epilepsy Jun 17, 2035 Jazz Pharms Res
Epidiolex US10195159 Processes and apparatus for extraction of active substances and enriched extracts from natural products May 07, 2022

(Expired)

 Jazz Pharms Res
Epidiolex US10603288 Use of cannabinoids in the treatment of epilepsy Jun 17, 2035 Jazz Pharms Res
Epidiolex US10709671 Use of cannabinoids in the treatment of epilepsy Jun 17, 2035 Jazz Pharms Res
Epidiolex US10709673 Use of cannabinoids in the treatment of epilepsy Jun 17, 2035 Jazz Pharms Res
Epidiolex US10709674 Use of cannabinoids in the treatment of epilepsy Jun 17, 2035 Jazz Pharms Res
Epidiolex US10849860 Use of cannabinoids in the treatment of epilepsy Jun 17, 2035 Jazz Pharms Res
Epidiolex US10918608 Use of cannabidiol in the treatment of epilepsy Oct 13, 2035 Jazz Pharms Res
Epidiolex US10966939 Use of cannabinoids in the treatment of epilepsy Jun 17, 2035 Jazz Pharms Res
Epidiolex US11065209 Use of cannabidiol in the treatment of epilepsy Oct 13, 2035 Jazz Pharms Res
Epidiolex US11096905 Use of cannabinoids in the treatment of epilepsy Oct 13, 2035 Jazz Pharms Res
Epidiolex US11154516 Use of cannabinoids in the treatment of epilepsy Jun 17, 2035 Jazz Pharms Res
Epidiolex US11160795 Methods of treating tuberous sclerosis complex with cannabidiol and everolimus Mar 01, 2041 Jazz Pharms Res
Epidiolex US11207292 Cannabidiol preparations and its uses Apr 26, 2039 Jazz Pharms Res
Epidiolex US11311498 Use of cannabinoids in the treatment of epilepsy Jun 17, 2035 Jazz Pharms Res
Epidiolex US11357741 Use of cannabinoids in the treatment of epilepsy Jun 17, 2035 Jazz Pharms Res
Epidiolex US11400055 Use of cannabidiol in the treatment of epilepsy Oct 13, 2035 Jazz Pharms Res
Epidiolex US11406623 Methods of treating tuberous sclerosis complex with cannabidiol and everolimus Mar 01, 2041 Jazz Pharms Res
Epidiolex US11446258 Use of cannabinoids in the treatment of epilepsy Jun 17, 2035 Jazz Pharms Res
Epidiolex US11633369 Use of cannabinoids in the treatment of epilepsy Jun 17, 2035 Jazz Pharms Res
Epidiolex US11701330 Use of cannabinoids in the treatment of epilepsy Jun 17, 2035 Jazz Pharms Res
Epidiolex US11766411 Use of cannabinoids in the treatment of epilepsy Jun 17, 2035 Jazz Pharms Res
Epidiolex US11865102 Cannabidiol preparations and its uses Apr 26, 2039 Jazz Pharms Res
Epidiolex US11963937 Use of cannabinoids in the treatment of epilepsy Jun 17, 2035 Jazz Pharms Res
Epidiolex US9949937 Use of cannabinoids in the treatment of epilepsy Jun 17, 2035 Jazz Pharms Res
Epidiolex US9956183 Use of cannabinoids in the treatment of epilepsy Jun 17, 2035 Jazz Pharms Res
Epidiolex US9956184 Use of cannabinoids in the treatment of epilepsy Jun 17, 2035 Jazz Pharms Res
Epidiolex US9956185 Use of cannabinoids in the treatment of epilepsy Jun 17, 2035 Jazz Pharms Res
Epidiolex US9956186 Use of cannabinoids in the treatment of epilepsy Jun 17, 2035 Jazz Pharms Res


Coming Soon

Patent Strength Analyzer

Will this be useful for you?

YesNo

Thank you for your response 🥳